LB Pharmaceuticals (LBRX) closed at $39.70 on October 30, 2026, down 1.1% from the previous close, on volume of 414,092 shares (30-day average 411,596).
Data as of October 30, 2026.
Analysts’ Top NA Picks: Guidewire (GWRE), LB Pharmaceuticals, Inc. (LBRX)
TipRanks (Wed, 28-Oct 8:02 AM ET)
BMO Capital Sticks to Their Buy Rating for LB Pharmaceuticals, Inc. (LBRX)
TipRanks (Wed, 28-Oct 7:48 AM ET)
LB Pharmaceuticals to Participate in Upcoming Investor Events
Globe Newswire (Thu, 15-Oct 4:05 PM ET)
LB Pharmaceuticals issues 400,000-option inducement grants as new CMO and CFO join
Market Chameleon (Mon, 12-Oct 7:30 AM ET)
Globe Newswire (Sat, 10-Oct 8:00 AM ET)
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 9-Oct 4:42 PM ET)
Globe Newswire (Tue, 6-Oct 8:00 AM ET)
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical Officer
Globe Newswire (Tue, 15-Sep 8:00 AM ET)
LB Pharmaceuticals to Participate in Upcoming September Investor Events
Globe Newswire (Thu, 3-Sep 4:05 PM ET)
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
Globe Newswire (Thu, 3-Sep 8:00 AM ET)
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
LB Pharmaceuticals trades on the NASDAQ stock market under the symbol LBRX.
As of October 30, 2026, LBRX stock price declined to $39.70 with 414,092 million shares trading.
LBRX has a beta of 1.52, meaning it tends to be more sensitive to market movements. LBRX has a correlation of 0.12 to the broad based SPY ETF.
LBRX has a market cap of $1.28 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that LBRX belongs to (by Net Assets): VTI, IWM, VXF, XPH, SCHA.
LBRX has outperformed the market in the last year with a price return of +153.7% while the SPY ETF gained +11.0%. However, in the short term, LBRX had mixed performance relative to the market. It has underperformed in the last 3 months, returning +1.8% vs +3.9% return in SPY. But in the last 2 weeks, LBRX shares have fared better than the market returning +8.2% compared to SPY -2.1%.
LBRX support price is $38.45 and resistance is $41.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LBRX shares will trade within this expected range on the day.
